News

Interplay between key proteins could serve as a target for cancer treatment
Immunotherapy uses a person's own immune system to fight cancer. Immune checkpoint inhibitors are one class of immunotherapy ...
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved
Moleculin Biotech's Q1 2025 earnings call highlights Phase 3 MIRACLE trial progress, EU regulatory signoff, patient enrollment milestones, and funding needs.